Literature DB >> 11169735

Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts.

C M Tummalapalli1, B J Heath, S C Tyagi.   

Abstract

Tumor cells become malignant, in part, because of their activation of matrix metalloproteinases (MMPs) and inactivation of tissue inhibitor of metalloproteinases (TIMPs). Myocardial tumors are rarely malignant. This raises the possibility that the MMPs and TIMPs are differentially regulated in the heart compared to other tissues. Therefore, we hypothesized that a tissue specific tumor suppressor exists in the heart. To test this hypothesis we prepared cardiac tissue extracts from normal (n = 4), ischemic cardiomypathic (ICM) [n = 5], and dilated cardiomyopathic (DCM) [n = 8] human heart end-stage explants. The level of cardiospecific TIMP-4 was determined by SDS-PAGE and Western-blot analysis. The results suggested reduced levels of TIMP-4 in ICM and DCM as compared to normal heart. TIMP-4 was purified by reverse phase HPLC and gelatin-sepharose affinity chromatography. Collagenase inhibitory activity of chromatographic peaks was determined using fluorescein-conjugated collagen as substrate and fluorescence spectroscopy. The activity of TIMP-4 (27 kDa) was characterized by reverse zymography. The role of TIMP-4 in cardiac fibroblast cell migration was examined using Boyden chamber analysis. The results suggested that TIMP-4 inhibited cardiac fibroblast cells migration and collagen gel invasion. To test whether TIMP-4 induces apoptosis, we cultured cardiac normal and polyomavirus transformed fibroblast cells in the presence and absence of TIMP-4. The number of cells were measured and DNA laddering was determined. The results suggested that TIMP-4 controlled normal cardiac fibroblast transformation and induced apoptosis in transformed cells. Cardiospecific TIMP-4 plays a significant role in regulating the normal cell phenotype. The reduced levels of TIMP-4 elicit cellular transformation and may lead to adverse extracellular matrix degradation (remodeling), cardiac hypertrophy and failure. This study suggests a possible protective role of TIMP-4 in other organs which are susceptible to malignancy. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169735     DOI: 10.1002/1097-4644(20010315)80:4<512::aid-jcb1005>3.0.co;2-n

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  25 in total

1.  Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.

Authors:  Anna Radomski; Paul Jurasz; Esmond J Sanders; Christopher M Overall; Heather F Bigg; Dylan R Edwards; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Arrhythmia and neuronal/endothelial myocyte uncoupling in hyperhomocysteinemia.

Authors:  Dorothea Rosenberger; Karni S Moshal; Ganesh K Kartha; Neetu Tyagi; Utpal Sen; David Lominadze; Claudio Maldonado; Andrew M Roberts; Suresh C Tyagi
Journal:  Arch Physiol Biochem       Date:  2006 Oct-Dec       Impact factor: 4.076

Review 3.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

4.  Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature.

Authors:  William M Yarbrough; Rupak Mukherjee; Robert E Stroud; William T Rivers; J Marshall Oelsen; Jennifer A Dixon; Shaina R Eckhouse; John S Ikonomidis; Michael R Zile; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-11-04       Impact factor: 5.209

5.  Synergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease.

Authors:  Srikanth Givvimani; Natia Qipshidze; Neetu Tyagi; Paras K Mishra; Utpal Sen; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-05-29

6.  Autophagy mechanism of right ventricular remodeling in murine model of pulmonary artery constriction.

Authors:  Natia Qipshidze; Neetu Tyagi; Naira Metreveli; David Lominadze; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-18       Impact factor: 4.733

7.  Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene.

Authors:  David A Young; Blaine W Phillips; Caroline Lundy; Robert K Nuttall; Aileen Hogan; Gilbert A Schultz; Kevin J Leco; Ian M Clark; Dylan R Edwards
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

Review 8.  Using proteomics to uncover extracellular matrix interactions during cardiac remodeling.

Authors:  Nicolle L Patterson; Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Yaojun Li; Thomas G Andrews; Gregory J Aune; Richard A Lange; Merry L Lindsey
Journal:  Proteomics Clin Appl       Date:  2013-07-08       Impact factor: 3.494

Review 9.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 10.  Matrix metalloproteinase in left ventricular remodeling and heart failure.

Authors:  Suresh Shastry; Melvin R Hayden; Pamela A Lucchesi; Suresh C Tyagi
Journal:  Curr Cardiol Rep       Date:  2003-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.